72
Participants
Start Date
February 24, 2015
Primary Completion Date
September 25, 2017
Study Completion Date
September 25, 2017
Naproxen
Take one 250mg naproxen tablet three times a day for 12 weeks.
Carbidopa/Levodopa
"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
Placebo
Take two placebo capsules three times a day for 12 weeks.
Northwestern University Feinberg School of Medicine, Chicago
National Institutes of Health (NIH)
NIH
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Northwestern University
OTHER